Skip to main content

Clinical Trials Using Gemcitabine

Review the clinical trials studying gemcitabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 137

Studying Chemotherapy with or without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Status: Active
Location: 321 locations
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Status: Active
Location: 319 locations
Comparing Impact of Treatment Before or After Surgery in Patients with Stage II-IIIB Resectable Non-small Cell Lung Cancer
Status: Active
Location: 325 locations
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Status: Active
Location: 229 locations
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Status: Active
Location: 148 locations
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Status: Active
Location: 126 locations
A Study Using Nivolumab, in Combination with Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Status: Active
Location: 77 locations
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy after Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Status: Active
Location: 81 locations
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Status: Active
Location: 57 locations
Testing the Combination of the Anticancer Drug Durvalumab with Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Status: Active
Location: 55 locations
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Status: Active
Location: 32 locations
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Status: Active
Location: 25 locations
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Status: Active
Location: 24 locations
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Status: Active
Location: 20 locations
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Active
Location: 18 locations
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Status: Active
Location: 16 locations
A Study of ASP3082 in Adults With Advanced Solid Tumors
Status: Active
Location: 16 locations
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Status: Active
Location: 12 locations
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Status: Active
Location: 15 locations
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Status: Active
Location: 15 locations
Gemcitabine and Oxaliplatin Chemotherapy with or without a Floxuridine and Dexamethasone Pump in Patients with Cholangiocarcinoma that Cannot Be Removed with Surgery
Status: Active
Location: 10 locations
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Status: Active
Location: 12 locations
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Status: Active
Location: 10 locations
Second-Line Pembrolizumab in Combination with Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Location: 10 locations
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Status: Active
Location: 10 locations